ARAY - Accuray Incorporated
MADISON, Wis., May 15, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced a new 10‑year strategic collaboration to advance personalized cancer treatments using Accuray's Stellar™ adaptive radiation therapy platform.
Accuray Incorporated (ARAY) Q3 2026 Earnings Call Transcript
MADISON, Wis., May 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter ended March 31, 2026.
MADISON, Wis., April 22, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2026, ended March 31, 2026, during a conference call hosted by company management at 1:30 p.m.
Accuray (NASDAQ: ARAY - Get Free Report) is anticipated to issue its Q3 2026 results after the market closes on Wednesday, April 29th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $111.90 million for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earning overview page for
MADISON, Wis., April 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026.
Accuray Incorporated (NASDAQ: ARAY - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 13th, there was short interest totaling 6,598,752 shares, a growth of 20.6% from the February 26th total of 5,471,116 shares. Approximately 5.8% of the shares of the company are sold
Accuray (NASDAQ: ARAY) executives used the company's fiscal second-quarter earnings call to outline progress on a broad transformation program while acknowledging that tariff impacts and geopolitical instability-particularly in China-pressured results and prompted a reset of full-year guidance. Transformation plan targets profitability and operational discipline CEO Steve La Neve said the company is executing a "comprehensive strategic,
Accuray Incorporated (ARAY) Q2 2026 Earnings Call Transcript
MADISON, Wis., Feb. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter ended December 31, 2025.
Acuitas Investments LLC increased its position in shares of Accuray Incorporated (NASDAQ: ARAY) by 67.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,392,126 shares of the medical equipment provider's stock after acquiring an additional 966,100 shares during the quarter.
MADISON, Wis., Jan. 21, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2026, ended December 31, 2025, during a conference call hosted by company management at 1:30 p.m.